On Tuesday, the U.S. Food and Drug Administration accepted AstraZeneca Plc's (NASDAQ: AZN) New Drug Application (NDA) for baxdrostat for adult patients with hard-to-control (uncontrolled or ...

For the millions of people with hypertension, the condition feels like a ticking time bomb. Those who have it can struggle to keep it under control, even with medication. Now, D.C.-area doctors are ...

Blood pressure control remains elusive for most adults in the U.S. with hypertension, although they are typically close enough to make control fairly straightforward, nationally representative data ...

Please provide your email address to receive an email when new articles are posted on . Lifetime risk for hypertension is up to 90% among U.S. adults. Updated guidelines and a pipeline of novel drugs ...

Aldosterone dysregulation plays an important pathogenic role in hard-to-control hypertension. In several studies, baxdrostat, an aldosterone synthase inhibitor, reduced the seated systolic blood ...